현대바이오, 전립선암 치료제 1상 변경 승인

Hyundai Bio's Phase 1 approval for CP-PCA07 marks meaningful progress in treating castration-resistant prostate cancer, where patients develop resistance to standard therapies and face limited treatment options. The combination approach with Enzalutamide could expand therapeutic choices for this underserved population, signaling Korea's growing strength in oncology innovation.